Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs

Radiolabeling strategies for tumor-targeting proteinaceous drugs.

Owing to their large size proteinaceous drugs offer higher operative information content compared to the small molecules that correspond to the traditional understanding of druglikeness. As a consequence these drugs allow developing patient-specific therapies that provide the means to go beyond the possibilities of current drug therapy. However, the efficacy of these strategies, in particular "...

Tumor Targeting Strategies

Nanoparticle-based drug delivery systems allow improved solubility, enhanced stability in circulation and multi-functionality. These properties and functions open many doors and create new biomedical applications for targeting drugs or imaging agents directly to the disease site. Due to the high incidence and mortality of cancer, studies are concentrating on targeted drug delivery to the tumor....

Radiolabeling of Ceftriaxone with 99mTc as a Targeting Radiopharmaceutical for Staphylococcus Aureus Detection in Mouse Model

Introduction Bacterial infection is one of the major causes of morbidity and mortality especially in developing countries. Nuclear medicine has an important role in helping the diagnosis of deep-seated infections by developing more specific radiopharmaceuticals. The aim of this study was to evaluate 99mTc-labeling ceftriaxone as a new radiopharmaceutical for Staphylococcus aureus infection imag...

Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications.

An engineered anti-carcinoembryonic antigen (CEA) diabody (scFv dimer, 55 kDa) was previously constructed from the murine anti-CEA T84.66 antibody. Tumor targeting, imaging and biodistribution studies in nude mice bearing LS174T xenografts with radiolabeled anti-CEA diabody demonstrated rapid tumor uptake and fast blood clearance, which are favorable properties for an imaging agent. Current rad...

Targeting Norovirus: Strategies for the Discovery of New Antiviral Drugs